Protease Inhibitor and Metabolic Alteration

Protease inhibitors (PIs), part of HAART (Highly Active Antiretroviral Therap) are selective, competitive inhibitors of protease, a crucial enzyme to viral maturation, infection and replication. A lipodystrophic syndrome has been reported in individuals treated with HAART, and associated to hypergly...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cavenaghi,F. M, Bataglion,C. A. N, Paula,P. C, Motta,A. C. F, Komesu,M. C
Lenguaje:	English
Publicado:	Sociedad Chilena de Anatomía 2012
Materias:	Protease inhibitors Dyslipidemia Metabolic disorders
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-95022012000200014
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0717-95022012000200014
record_format	dspace
spelling	oai:scielo:S0717-950220120002000142012-10-03Protease Inhibitor and Metabolic AlterationCavenaghi,F. MBataglion,C. A. NPaula,P. CMotta,A. C. FKomesu,M. C Protease inhibitors Dyslipidemia Metabolic disorders Protease inhibitors (PIs), part of HAART (Highly Active Antiretroviral Therap) are selective, competitive inhibitors of protease, a crucial enzyme to viral maturation, infection and replication. A lipodystrophic syndrome has been reported in individuals treated with HAART, and associated to hyperglycemia, hypercholesterolemia, hypertrigliceridemia, hyperlipidemia, hypertension and hypreinsulinemia. The HAART-associated metabolic abnormalities were first associated with protease inhibitors, Ritonavir mostly, but the mechamisns that underlie these metabolic alterations are to date, not completely understood. Since PIs are candidate to be the drug of choice for other diseases treatment, such as the Hepatitis C, malaria and some types of cancer, it seems to be important to clarify the metabolic alterations associated to PIs. Wistar rats were treated twice a week with 30mg/kg Ritonavir for 4 and 8 weeks. Total cholesterol, HDL, LDL, VLDL, triglycerides and glycemic levels were measured by the end of each period of time selected. To avoid confunding effects of food intake, the animals were fasted 16 hours before. Our results showed rapid increase in serum triglycerides, total cholesterol, LDL-C and glycemic levels. No significant differences were observed for HDL-C or VLDL serum levels. Our study addresses the importance to observe the possible family history of dyslipidemia or diabetes, and control any other cardiovascular and diabetes risk factors when using protease inhibitors.info:eu-repo/semantics/openAccessSociedad Chilena de AnatomíaInternational Journal of Morphology v.30 n.2 20122012-06-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-95022012000200014en10.4067/S0717-95022012000200014
institution	Scielo Chile
collection	Scielo Chile
language	English
topic	Protease inhibitors Dyslipidemia Metabolic disorders
spellingShingle	Protease inhibitors Dyslipidemia Metabolic disorders Cavenaghi,F. M Bataglion,C. A. N Paula,P. C Motta,A. C. F Komesu,M. C Protease Inhibitor and Metabolic Alteration
description	Protease inhibitors (PIs), part of HAART (Highly Active Antiretroviral Therap) are selective, competitive inhibitors of protease, a crucial enzyme to viral maturation, infection and replication. A lipodystrophic syndrome has been reported in individuals treated with HAART, and associated to hyperglycemia, hypercholesterolemia, hypertrigliceridemia, hyperlipidemia, hypertension and hypreinsulinemia. The HAART-associated metabolic abnormalities were first associated with protease inhibitors, Ritonavir mostly, but the mechamisns that underlie these metabolic alterations are to date, not completely understood. Since PIs are candidate to be the drug of choice for other diseases treatment, such as the Hepatitis C, malaria and some types of cancer, it seems to be important to clarify the metabolic alterations associated to PIs. Wistar rats were treated twice a week with 30mg/kg Ritonavir for 4 and 8 weeks. Total cholesterol, HDL, LDL, VLDL, triglycerides and glycemic levels were measured by the end of each period of time selected. To avoid confunding effects of food intake, the animals were fasted 16 hours before. Our results showed rapid increase in serum triglycerides, total cholesterol, LDL-C and glycemic levels. No significant differences were observed for HDL-C or VLDL serum levels. Our study addresses the importance to observe the possible family history of dyslipidemia or diabetes, and control any other cardiovascular and diabetes risk factors when using protease inhibitors.
author	Cavenaghi,F. M Bataglion,C. A. N Paula,P. C Motta,A. C. F Komesu,M. C
author_facet	Cavenaghi,F. M Bataglion,C. A. N Paula,P. C Motta,A. C. F Komesu,M. C
author_sort	Cavenaghi,F. M
title	Protease Inhibitor and Metabolic Alteration
title_short	Protease Inhibitor and Metabolic Alteration
title_full	Protease Inhibitor and Metabolic Alteration
title_fullStr	Protease Inhibitor and Metabolic Alteration
title_full_unstemmed	Protease Inhibitor and Metabolic Alteration
title_sort	protease inhibitor and metabolic alteration
publisher	Sociedad Chilena de Anatomía
publishDate	2012
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-95022012000200014
work_keys_str_mv	AT cavenaghifm proteaseinhibitorandmetabolicalteration AT bataglioncan proteaseinhibitorandmetabolicalteration AT paulapc proteaseinhibitorandmetabolicalteration AT mottaacf proteaseinhibitorandmetabolicalteration AT komesumc proteaseinhibitorandmetabolicalteration
_version_	1718444776185921536

Protease Inhibitor and Metabolic Alteration

Ejemplares similares